The present disclosure provides systems for growing and, modeling lung cells in organoid cultures and methods of using same.

The present disclosure provides compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for immunotherapy in cancer or infection.

Embodiments of the disclosure include methods of increasing the efficacy of a fibroblast cell therapy for any medical condition, including degenerative disc disease, by providing at least one anti-inflammatory composition, exosomes and/or apoptotic bodies, stem cells, or a combination thereof; and administering the fibroblast cell therapy. The anti-inflammatory composition may comprise a composition that inhibits and/or reduces TNF-alpha, such as melatonin.

Embodiments of the disclosure concern methods and compositions for immunotherapy for human papillomavirus infection and diseases associated therewith. In specific embodiments, methods concern production of immune cells that target one or more antigens of HPV16 and/or HPV18, including methods with stimulation steps that employ IL-7 and IL-15, but not IL-6 and/or IL-12. Other specific embodiments utilize stimulations in the presence of certain cells, such as costimulatory cells and certain antigen presenting cells.

One aspect of the present disclosure can include a priming medium for creating an isolated population of stem cells having an anti-inflammatory phenotype from an unprimed population of stem cells. The priming media can include a serum-free medium, a functional activator of a Type I interferon (IFN) pathway and a Type II IFN pathway, and at least two pro-inflammatory cytokines. The functional activator and the at least two pro-inflammatory cytokines can be present in an amount sufficient to promote induction of stem cells having an anti-inflammatory phenotype. The cells having an anti-inflammatory phenotype can be marked by increased expression and/or secretion of one or more anti-inflammatory or immune modulatory mediators as compared to the unprimed population of stem cells. Other aspects of the present disclosure can include stem cells made according to the present disclosure as well as therapeutic compositions and uses of the stem cells.

Provided herein are methods for ex vivo expansion of a T cells, including tumor-reactive T cells, and compositions containing such T cells. Also provided are methods for treating diseases and conditions such as cancer using compositions of the present disclosure.

A decidual placental mesenchymal stem cell and its culturing method are provided, which includes adding an induction step to the conventional mesenchymal stem cell culture method to make the said decidual placental mesenchymal stem cell highly express the decoy receptor 3; DcR3. A use of decidual placental mesenchymal stem cells for preparing pharmaceutical compositions for promoting angiogenesis.

The present application provides a method for preparing mesenchymal stem cell-derived exosomes, the method including: obtaining a cell sample from mesenchymal stem cells and sub-culturing the cell sample, culturing the sub-cultured cells in a substrate medium containing a protein synthesis inhibitory enzyme, and then obtaining a cell culture solution, and isolating exosomes from the cell culture solution, and a cell culture solution produced therefrom. The method for preparing exosomes of the present application has an advantage in that high purity and high concentration exosomes can be isolated.

Glycoproteins that are transgenically produced in mammalian cells exhibit non-human glycan structures. As in humans, this can possibly lead to immune responses, the drug manufacturing potential of these drugs is limited. On the other hand, recombinant protein production in human cells is inefficient due to the cells' poor protein yields, proliferation potential and cellular density. The present application solves these issues by providing a recombinant vertebrate cell that is comprising a non-vertebrate and/or artificial phosphatidylethanolamine-binding protein (PEBP). Compared to a parent cell line, the recombinant cells of the invention exhibit improved cell growth, protein yield and excellent compatibility with other established protein production methods. Furthermore, methods, for producing a cell line with improved vitality, protein expression and cell growth characteristics by introducing a non-vertebrate and/or artificial PEBP is given. Moreover, both a nucleic acid construct that is suitable for regulating recombinant protein expression in a cell by coding for such a PEBP and a recombinant cell comprising such a nucleic acid construct is provided. Lastly, a method for the recombinant expression of a target protein by culturing such a recombinant vertebrate cell of the invention is given, wherein the cell is also comprising an expression construct encoding the target protein.

The present disclosure provides methods of generating HLA class-I null cells that can be used for expression of exogenous HLA genes and presentation of antigens, such tumor neoantigens. Method for using HLA class-I null cells from selecting, stimulating and propagating immune effector cells are also provided.